319 related articles for article (PubMed ID: 15839837)
21. Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
Xuan JA; Schneider D; Toy P; Lin R; Newton A; Zhu Y; Finster S; Vogel D; Mintzer B; Dinter H; Light D; Parry R; Polokoff M; Whitlow M; Wu Q; Parry G
Cancer Res; 2006 Apr; 66(7):3611-9. PubMed ID: 16585186
[TBL] [Abstract][Full Text] [Related]
22. Biochemical characterization of prostasin, a channel activating protease.
Shipway A; Danahay H; Williams JA; Tully DC; Backes BJ; Harris JL
Biochem Biophys Res Commun; 2004 Nov; 324(2):953-63. PubMed ID: 15474520
[TBL] [Abstract][Full Text] [Related]
23. Hepsin and prostate cancer.
Wu Q; Parry G
Front Biosci; 2007 Sep; 12():5052-9. PubMed ID: 17569629
[TBL] [Abstract][Full Text] [Related]
24. Pegylated kunitz domain inhibitor suppresses hepsin-mediated invasive tumor growth and metastasis.
Li W; Wang BE; Moran P; Lipari T; Ganesan R; Corpuz R; Ludlam MJ; Gogineni A; Koeppen H; Bunting S; Gao WQ; Kirchhofer D
Cancer Res; 2009 Nov; 69(21):8395-402. PubMed ID: 19843851
[TBL] [Abstract][Full Text] [Related]
25. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.
Lee SL; Dickson RB; Lin CY
J Biol Chem; 2000 Nov; 275(47):36720-5. PubMed ID: 10962009
[TBL] [Abstract][Full Text] [Related]
26. Roles and regulation of membrane-associated serine proteases.
Qiu D; Owen K; Gray K; Bass R; Ellis V
Biochem Soc Trans; 2007 Jun; 35(Pt 3):583-7. PubMed ID: 17511657
[TBL] [Abstract][Full Text] [Related]
27. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
[TBL] [Abstract][Full Text] [Related]
28. An allosteric anti-hepsin antibody derived from a constrained phage display library.
Ganesan R; Zhang Y; Landgraf KE; Lin SJ; Moran P; Kirchhofer D
Protein Eng Des Sel; 2012 Mar; 25(3):127-33. PubMed ID: 22258274
[TBL] [Abstract][Full Text] [Related]
29. Pericellular activation of hepatocyte growth factor/scatter factor (HGF/SF) in colorectal carcinomas: roles of HGF activator (HGFA) and HGFA inhibitor type 1 (HAI-1).
Kataoka H; Itoh H; Hamasuna R; Meng JY; Koono M
Hum Cell; 2001 Mar; 14(1):83-93. PubMed ID: 11436357
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Selective Matriptase and Hepsin Serine Protease Inhibitors: Useful Chemical Tools for Cancer Cell Biology.
Damalanka VC; Han Z; Karmakar P; O'Donoghue AJ; La Greca F; Kim T; Pant SM; Helander J; Klefström J; Craik CS; Janetka JW
J Med Chem; 2019 Jan; 62(2):480-490. PubMed ID: 30571119
[TBL] [Abstract][Full Text] [Related]
32. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate.
Knudsen BS; Lucas JM; Fazli L; Hawley S; Falcon S; Coleman IM; Martin DB; Xu C; True LD; Gleave ME; Nelson PS; Ayala GE
Am J Pathol; 2005 Jul; 167(1):255-66. PubMed ID: 15972969
[TBL] [Abstract][Full Text] [Related]
33. Probing the substrate specificities of matriptase, matriptase-2, hepsin and DESC1 with internally quenched fluorescent peptides.
Béliveau F; Désilets A; Leduc R
FEBS J; 2009 Apr; 276(8):2213-26. PubMed ID: 19302215
[TBL] [Abstract][Full Text] [Related]
34. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis.
Marchand-Adam S; Fabre A; Mailleux AA; Marchal J; Quesnel C; Kataoka H; Aubier M; Dehoux M; Soler P; Crestani B
Am J Respir Crit Care Med; 2006 Jul; 174(1):58-66. PubMed ID: 16574935
[TBL] [Abstract][Full Text] [Related]
35. Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression.
Tripathi M; Nandana S; Yamashita H; Ganesan R; Kirchhofer D; Quaranta V
J Biol Chem; 2008 Nov; 283(45):30576-84. PubMed ID: 18784072
[TBL] [Abstract][Full Text] [Related]
36. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.
Humphrey PA; Zhu X; Zarnegar R; Swanson PE; Ratliff TL; Vollmer RT; Day ML
Am J Pathol; 1995 Aug; 147(2):386-96. PubMed ID: 7639332
[TBL] [Abstract][Full Text] [Related]
37. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma.
Kataoka H; Hamasuna R; Itoh H; Kitamura N; Koono M
Cancer Res; 2000 Nov; 60(21):6148-59. PubMed ID: 11085539
[TBL] [Abstract][Full Text] [Related]
38. Synthesis of positional-scanning libraries of fluorogenic peptide substrates to define the extended substrate specificity of plasmin and thrombin.
Backes BJ; Harris JL; Leonetti F; Craik CS; Ellman JA
Nat Biotechnol; 2000 Feb; 18(2):187-93. PubMed ID: 10657126
[TBL] [Abstract][Full Text] [Related]
39. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.
Peek M; Moran P; Mendoza N; Wickramasinghe D; Kirchhofer D
J Biol Chem; 2002 Dec; 277(49):47804-9. PubMed ID: 12372819
[TBL] [Abstract][Full Text] [Related]
40. In vitro evidence that KLK14 regulates the components of the HGF/Met axis, pro-HGF and HGF-activator inhibitor 1A and 1B.
Reid JC; Bennett NC; Stephens CR; Carroll ML; Magdolen V; Clements JA; Hooper JD
Biol Chem; 2016 Dec; 397(12):1299-1305. PubMed ID: 27533117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
